Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedUpdated the page to v3.2.0 with a government-operating status notice and related links; removed the previous v3.1.0 reference.SummaryDifference2%

- Check22 days agoChange DetectedUpdates add current dates, new locations/addresses, and an updated revision version; older locations and outdated addresses are removed. Overall, it reflects a refresh of core identifiers and contact details.SummaryDifference3%

- Check37 days agoChange DetectedLocalized the country name from Mexico to México in the address and updated the revision to v3.0.2; the 'Back to Top' link was removed.SummaryDifference1%

- Check44 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

- Check51 days agoChange DetectedThe web page has been updated to include new facility names and locations, increasing the total number of study locations from 187 to 189. Additionally, the last update date has been changed to August 2025.SummaryDifference14%

- Check66 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.0%

Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.